EvenBetter99
$CLRB Cellectar Biosciences' CLOVER WaM results are a clinical triumph! Iopofosine I 131 achieved an extraordinary 87.5% overall response rate, 79.2% major response rate, and 100% clinical benefit in post-BTKi Waldenström patients. With durable 16-month responses and 19.1 months of treatment-free survival, this breakthrough sets up a massive 1H27 FDA accelerated approval filing! 🔥🔥🔥🔥🔥🔥
1
2

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault41.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault19.jpg)
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_stock_rising_resized_f17852d7aa.jpg)